Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

SML2400

Sigma-Aldrich

LW106

>97% (HPLC)

Synonym(s):

(4-Amino-1,2,5-oxadiazol-3-yl)(1,3-dihydro-2H-isoindol-2-yl)-methanone oxime, (E)-(4-Amino-1,2,5-oxadiazol-3-yl)(isoindolin-2-yl)methanone oxime

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C11H11N5O2
CAS Number:
Molecular Weight:
245.24
UNSPSC Code:
12352200

assay

>97% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O/N=C(C1=NON=C1N)/N2CC3=CC=CC=C3C2

Biochem/physiol Actions

Indoleamine 2,3-dioxygenase 1 (IDO; IDO1) inhibitor with better in vivo antitumor efficacy than Epacadostat (INCB024360).
LW106 is an indoleamine 2,3-dioxygenase 1 (IDO; IDO1) inhibitor (IC50 = 13 nM) that effectively inhibits kynurenine production upon cellular IDO1 upregulation by IFNγ induction (50 ng/mL, 48 h) in HeLa cultures (IC50 = 1.57 μM) and prevents the antiproliferation activity of IDO1-positive DCs against co-cultured CD8+ T-cells (proliferation suppression = 67% with vehicle vs. 33% with 20 μM LW106). LW106 exhibits antitumor activity only in immunocompetent, but not athymic or IDO1-/-, mice, displaying better in vivo efficacy than Epacadostat (Lewis lung carcinoma/B16-F10 tumor suppression = 68%/65% with LW106 vs. 51%/50% with Epacadostat; 80 mg/kg/day i.p.).

Storage Class

13 - Non Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rong Fu et al.
British journal of pharmacology, 175(14), 3034-3049 (2018-05-04)
Indoleamine 2,3-dioxygenase 1 (IDO1) is emerging as an important new therapeutic target for treatment of malignant tumours characterized by dysregulated tryptophan metabolism. However, the antitumour efficacy of existing small-molecule inhibitors of IDO1 is still unsatisfactory and the underlying mechanism remains

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service